Chronic constipation is a prevalent, burdensome gastrointestinal disorder whose treatment remains challenging. There exist effective pharmacological therapies for chronic constipation, however, many patients do not well respond to current medications. Evidence suggests that disturbance in the gastrointestinal microbiota may be implicated in chronic constipation. Although, E.coli Nissle 1917 (Mutaflor®) has been used for chronic constipation, there are limited data regarding the efficacy of E.coli Nissle 1917 (Mutaflor®) in these patients. Therefore, this study aimed to investigate the efficacy of E.coli Nissle 1917 (Mutaflor®) in patients with chronic constipation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
112
Yoo Jin Lee
Daegu, South Korea
Relief of constipation defined by improvement of complete spontaneous bowel movements(CSBMs/week)
Subjects will report symptoms by questionnaire
Time frame: 28days
Improvement of average number of CSBMs/week
Subjects will report symptoms by questionnaire
Time frame: 28days
The time to 1st CSBM or SBM
Subjects will report symptoms by questionnaire
Time frame: 28days
Improvement of constipation related quality of life
Subjects will report symptoms by questionnaire
Time frame: 28days
Improvement of constipation related symptom
Subjects will report symptoms by questionnaire
Time frame: 28days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.